特雷维治疗

最新新闻

• 评级变动
  BMO Capital Maintains Trevi Therapeutics(TRVI.US) With Buy Rating, Maintains Target Price $36
  \u5e02\u573a\u8d44\u8baf · 2026/7/21
• JonesTrading Maintains Trevi Therapeutics(TRVI.US) With Buy Rating, Raises Target Price to $28
  \u5e02\u573a\u8d44\u8baf · 2026/8/14
• 评级变动
  Trevi Therapeutics (TRVI) Receives a New Rating From B. Riley Securities
  TipRanks · 2026/8/7
• 评级变动
  Clear Street Maintains Trevi Therapeutics(TRVI.US) With Buy Rating, Raises Target Price to $29
  \u5e02\u573a\u8d44\u8baf · 2026/5/8
• 评级变动
  Oppenheimer Maintains Trevi Therapeutics(TRVI.US) With Buy Rating, Raises Target Price to $25
  \u5e02\u573a\u8d44\u8baf · 2026/8/7
• 评级变动
  BMO Capital Initiates Trevi Therapeutics(TRVI.US) With Buy Rating, Announces Target Price $36
  \u5e02\u573a\u8d44\u8baf · 2026/7/21
• 评级变动
  H.C. Wainwright Maintains Trevi Therapeutics(TRVI.US) With Buy Rating, Maintains Target Price $21
  \u5e02\u573a\u8d44\u8baf · 2026/5/8
• Trevi Therapeutics (TRVI) Receives a Buy From H.C. Wainwright
  TipRanks · 2026/9/22
• 评级变动
  Needham Maintains Trevi Therapeutics(TRVI.US) With Buy Rating, Maintains Target Price $23
  \u5e02\u573a\u8d44\u8baf · 2026/7/17
• 评级变动
  A Quick Look at Today's Ratings for Trevi Therapeutics(TRVI.US), With a Forecast Between $18 to $23
  \u5e02\u573a\u8d44\u8baf · 2026/5/6
• 评级变动
  Stifel Maintains Trevi Therapeutics(TRVI.US) With Buy Rating, Maintains Target Price $30
  \u5e02\u573a\u8d44\u8baf · 2026/8/7
• 评级变动
  Needham Maintains Trevi Therapeutics(TRVI.US) With Buy Rating, Maintains Target Price $24
  \u5e02\u573a\u8d44\u8baf · 2026/4/14
• H.C. Wainwright Maintains Trevi Therapeutics(TRVI.US) With Buy Rating, Maintains Target Price $24
  \u5e02\u573a\u8d44\u8baf · 2026/9/22
• 评级变动
  Stifel Maintains Trevi Therapeutics(TRVI.US) With Buy Rating, Raises Target Price to $30
  \u5e02\u573a\u8d44\u8baf · 2026/5/8
• H.C. Wainwright Maintains Trevi Therapeutics(TRVI.US) With Buy Rating, Raises Target Price to $24
  \u5e02\u573a\u8d44\u8baf · 2026/7/20
• Morgan Stanley Maintains Trevi Therapeutics(TRVI.US) With Buy Rating, Maintains Target Price $23
  \u5e02\u573a\u8d44\u8baf · 2026/8/10
• 评级变动
  Morgan Stanley Maintains Trevi Therapeutics(TRVI.US) With Buy Rating, Raises Target Price to $23
  \u5e02\u573a\u8d44\u8baf · 2026/8/7
• 评级变动
  JonesTrading Maintains Trevi Therapeutics(TRVI.US) With Buy Rating, Maintains Target Price $24
  \u5e02\u573a\u8d44\u8baf · 2026/5/7
• 评级变动
  Oppenheimer Maintains Trevi Therapeutics(TRVI.US) With Buy Rating, Maintains Target Price $24
  \u5e02\u573a\u8d44\u8baf · 2026/5/8
• 评级变动
  A Quick Look at Today's Ratings for Trevi Therapeutics(TRVI.US), With a Forecast Between $23 to $40
  \u5e02\u573a\u8d44\u8baf · 2026/8/8

新闻标题为自动聚合内容，未经我们团队独立核实或编辑。